NCT01727141
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
Phase: Phase 3
Role: Lead Sponsor
Start: Nov 30, 2012
Completion: Feb 28, 2014